Literature DB >> 29883971

An Overview of FGF19 and FGF21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity.

Nasim Babaknejad1,2,3, Hashem Nayeri3, Roohullah Hemmati2, Somaye Bahrami3, Ahmad Esmaillzadeh4,5,6.   

Abstract

Fibroblast growth factors (FGFs) are responsible for the regulation of a wide range of biological functions, among which cellular proliferation, survival, migration, and differentiation could be pointed out. FGF19 controls the enterohepatic bile acid/cholesterol system, and FGF21 modulates fatty acid/glucose metabolism. Obesity, type 2 diabetes, coronary artery disease, and cancer, all can alter FGF21 circulating concentrations. In contrast to FGF21, metabolic diseases exhibit reduced serum FGF19 levels. Accordingly, FGF19 and FGF21 play important roles in regulating glucose and lipid metabolism. Hence, we present here a timely review on the relationship between FGF19/21 and metabolic diseases, especially obesity, and their probable role in development and treatment of obesity seems necessary. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29883971     DOI: 10.1055/a-0623-2909

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  19 in total

Review 1.  Metabolic communication during exercise.

Authors:  Robyn M Murphy; Matthew J Watt; Mark A Febbraio
Journal:  Nat Metab       Date:  2020-08-03

2.  The stimulatory effects of glucagon on cortisol and GH secretion occur independently from FGF-21.

Authors:  Ilyas Akkar; Zuleyha Karaca; Serpil Taheri; Kursad Unluhizarci; Aysa Hacioglu; Fahrettin Kelestimur
Journal:  Endocrine       Date:  2021-09-25       Impact factor: 3.633

Review 3.  Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Authors:  Marta Latko; Aleksandra Czyrek; Natalia Porębska; Marika Kucińska; Jacek Otlewski; Małgorzata Zakrzewska; Łukasz Opaliński
Journal:  Cells       Date:  2019-05-14       Impact factor: 6.600

4.  Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21.

Authors:  Ting Hong; Zhijuan Ge; Bingjie Zhang; Ran Meng; Dalong Zhu; Yan Bi
Journal:  Int J Mol Med       Date:  2019-05-28       Impact factor: 4.101

5.  Fibroblast Growth Factor 19 Levels Predict Subclinical Atherosclerosis in Men With Type 2 Diabetes.

Authors:  Jingyi Hu; Zhiwen Liu; Yue Tong; Zubing Mei; Aimin Xu; Pengcheng Zhou; Xiaoyan Chen; Weili Tang; Zhiguang Zhou; Yang Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-22       Impact factor: 5.555

6.  Serum Fibroblast Growth Factor 19 and Total Bile Acid Concentrations Are Potential Biomarkers of Hepatocellular Carcinoma in Patients with Type 2 Diabetes Mellitus.

Authors:  Yi Sun; Minxia Zhu; Hui Zhao; Xiaoqing Ni; Renan Chang; Jianyou Su; Hua Huang; Shiwei Cui; Xinlei Wang; Jin Yuan; Jie Yuan; Rong OuYang; Rongping Zhang; Wei Chen; Yunjuan Gu; Yezi Sun
Journal:  Biomed Res Int       Date:  2020-02-11       Impact factor: 3.411

7.  Hypolipidemic Roles of Casein-Derived Peptides by Regulation of Trans-Intestinal Cholesterol Excretion and Bile Acid Synthesis.

Authors:  Sungmin Lee; BuHyun Youn
Journal:  Nutrients       Date:  2020-10-06       Impact factor: 5.717

8.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

9.  Adipocyte epigenetic alterations and potential therapeutic targets in transgenerationally inherited lean and obese phenotypes following ancestral exposures.

Authors:  Stephanie E King; Eric Nilsson; Daniel Beck; Michael K Skinner
Journal:  Adipocyte       Date:  2019-12       Impact factor: 4.534

Review 10.  Fibroblast Growth Factor 21 and the Adaptive Response to Nutritional Challenges.

Authors:  Úrsula Martínez-Garza; Daniel Torres-Oteros; Alex Yarritu-Gallego; Pedro F Marrero; Diego Haro; Joana Relat
Journal:  Int J Mol Sci       Date:  2019-09-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.